Jun 1, 2021 • 7:05 am EDT Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
May 25, 2021 • 8:05 am EDT Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
May 13, 2021 • 8:05 am EDT Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Apr 20, 2021 • 8:05 am EDT Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Mar 30, 2021 • 8:05 am EDT Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Mar 15, 2021 • 7:05 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
Mar 8, 2021 • 8:05 am EST Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021